Brief Communication
using specific biotinylated primers directed towards 43 known spacers, interspersed between the DR-cluster of MTB genome. The amplicons were hybridised using streptavidin-conjugate on an activated membrane to which spacer oligonucleotides were covalently bound. For detection of hybridised DNA, an enhanced chemiluminescence detection system was used. The membrane was reversely blotted on an X-ray film to record the hybridisation signals. H37Rv was used as positive control and distilled water as negative control. The presence/absence of spacer oligonucleotides was documented in the form of binary code that was converted into octal code.
Spoligotype patterns analysis
The spoligotype patterns were analysed using the SITVIT2 database (Institut Pasteur de la Guadeloupe) to assign spoligotype lineages. [4] A strain was defined as 'cluster' when two or more strains were found to have same spoligotype international type (SIT); as 'unique' when a single strain was found to have specific SIT and as 'orphan' when no match for SIT for a strain was found in the database. [5, 6] 
Results
Out of a total 46 strains in 2007, 24 (52.17%) could be clustered in 3 SITs; 10 (21.73%) were unique and 12 (26.08%) were orphan strains. ST11/EAI3_IND, ST26/CAS1_Del and ST288/ CAS2 with 13 (28.26%), 7 (15.21%) and 4 (8.69%) strains, respectively, were the three predominant lineages in 2007. Out of a total 64 strains in 2008, 40 (62.5%) could be clustered in 5 SITs, 06 (9.37%) were unique and 18 (28.12%) were orphan strains. ST26/CAS1_Del, ST11/EAI3_IND, and ST25/CAS1_ Del with 17 (26.56%), 13 (20.31%) and 06 (9.37%) strains, respectively, were the three predominant lineages in 2008. Out of a total 79 strains in 2009, 51 (64.55%) could be clustered in 11 SITs, 18 (22.78%) were unique and 10 (12.65%) were orphan strains. ST26/CAS1_Del, ST11/EAI3_IND and ST25/CAS1_Del with 18 (22.78%), 8 (10.12%) and 4 (5.06%) strains, respectively, were the three predominant lineages in 2009. Out of a total 70 strains in 2010, 48 (68.57%) could be clustered in 7 SITs, 14 (20%) were unique and 8 (11.42%) were orphan strains. ST26/CAS1_Del, ST11/EAI3_IND and ST288/CAS2 with 18 (22.78%), 8 (10.12%) and 4 (5.06%) strains, respectively, were the three predominant lineages in 2010. Out of a total 81 strains in 2011, 48 (59.25%) could be clustered in 8 SITs, 20 (24.69%) were unique and 13 (16.04%) were orphan strains. ST26/CAS1_Del with 18 (22.22%), ST11/ EAI3_IND with 11 (13.58%), ST288/CAS2 and ST25/CAS1_ Del with 5 (6.17%) strains each were the predominant lineages in 2011. The prevalence of ST11/EAI3_IND decreased over the initial 3 years from 28.26% strains in 2007 to 10.12% strains in 2009, increased to 24.28% strains in 2010 and again decreased to 13.58% in 2011. The prevalence ST26/CAS1_Del lineage increased from 15.21% of the strains in 2007 to 26.56% in 2008, reduced to 22.78% in 2009, again increased to 25.71% in 2010 and again decreased to 22.22% in 2011. The prevalence of Beijing strain increased from 2.17% strains in 2007 to 5.06% in 2009 and then, reduced over the next 2 years to 3.7% of strains in 2011 [ Figure 1 ]. The prevalence of orphan strains increased from 26.08% of the strains in 2007 to 28.12% in 2008, reduced over the next 2 years to 11.42% in 2010 and increased to 16.04% in 2011.
discussion
The long-standing association of MTB and humans since ancient times indicates some adaptive genetic changes in the pathogen. The emerging multidrug resistance [7] among the strains of MTB is the classic paradigm of adaptation. MTB can exist in diverse metabolic states, following genetic alterations that help its escape through the conventional anti-tuberculosis agents. [8] Study of mobile genetic elements or repetitive DNA segments has enhanced our knowledge on 'ancestral' and 'modern' strains of MTB which may be related to a possible adaptive mechanism in the pathogen. [9, 10] In our study, the two foremost lineages, the 'ancient' ST11/EAI3_IND and the 'modern' ST26/CAS1_Del were found to be well established over 5 years. However, the prevalence of these lineages alternately increased and decreased over each consecutive year till 2011. Continuous clustering of EAI and CAS lineages indicates that these lineages are well adapted to this area, and therefore, show a successful transmission. The CAS and EAI lineages have shown consistent predominance and clustering patterns in the Indian subcontinent for many years. [5, 11] The EAI lineage has always been found to be prevalent in South India. [11] In the present study, ST11/EAI3_IND and ST26/CAS1_Del showed waxing and waning trends of prevalence over the 5 years of study.
The more recently evolved Beijing genotype was not a predominant lineage in this region though it had a continuous representation. Beijing lineage is well known for its virulent nature and its association with drug resistance. [12] The prevalence of other predominant lineages, ST288/CAS2 and ST25/CAS1_Del lineages also showed waxing and waning trends over the period of study [ Figure 1 ]. Poorly represented lineages appeared and disappeared intermittently over 5 years [ Table 1 ]. These lineages may have not been able to gain a foothold in this region. This is similar to the findings from a study from New Delhi, India. [13] On the other hand, MANU, a poorly represented lineage in our area, was found to be the most predominant lineage among the drug-susceptible strains of MTB in Mumbai, India. [14] conclusion Well-established lineages show a consistent presence in the community. ST26/CAS1_Del and ST11/EAI3_IND lineages were consistently present and were the most predominant lineages over 5 years. Beijing lineage had a continuous, though less predominant presence. Other poorly represented lineages appeared and disappeared intermittently. It is possible that a mix of host, environmental and bacterial factors is involved in the propagation success of some lineages and poor propagation of others. These factors may vary from region to region. Identification and mapping of these factors may help plan strategies for targeted and successful control of tuberculosis. 
